Changes	O
in	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
levels	O
in	O
non	B-Cancer
-	I-Cancer
small	I-Cancer
cell	I-Cancer
lung	I-Cancer
cancer	I-Cancer
.	O

Increased	O
urokinase	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
levels	O
are	O
increased	O
in	O
a	O
number	O
of	O
malignancies	B-Cancer
and	O
have	O
been	O
correlated	O
with	O
decreased	O
disease	O
-	O
free	O
interval	O
and	O
decreased	O
overall	O
survival	O
.	O

We	O
have	O
,	O
therefore	O
,	O
examined	O
components	O
of	O
this	O
plasminogen	O
activating	O
system	O
in	O
patients	O
with	O
Non	B-Cancer
-	I-Cancer
Small	I-Cancer
Cell	I-Cancer
Lung	I-Cancer
Cancer	I-Cancer
(	O
NSCLC	B-Cancer
)	O
.	O

Levels	O
of	O
uPA	O
,	O
urokinase	O
-	O
plasminogen	O
activator	O
receptor	O
(	O
uPAR	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
were	O
measured	O
semiquantitatively	O
in	O
paraffin	B-Cancer
sections	I-Cancer
of	O
tumours	B-Cancer
from	O
147	O
patients	O
with	O
NSCLC	B-Cancer
.	O

Immunohistochemically	O
stained	O
sections	B-Cancer
of	O
tumour	B-Cancer
were	O
allocated	O
a	O
score	O
for	O
stain	O
intensity	O
and	O
results	O
correlated	O
to	O
:	O
survival	O
;	O
tumour	B-Cancer
stage	O
(	O
T	O
)	O
;	O
nodal	B-Multi-tissue_structure
stage	O
(	O
N	O
)	O
;	O
stage	O
grouping	O
(	O
I	O
to	O
IIIb	O
)	O
,	O
survival	O
status	O
and	O
sex	O
.	O

Increased	O
levels	O
of	O
PAI	O
-	O
1	O
were	O
associated	O
with	O
a	O
decreased	O
survival	O
in	O
squamous	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
(	O
SCC	B-Cancer
)	O
X2	O
=	O
5	O
.	O
72	O
,	O
p	O
=	O
0	O
.	O
017	O
(	O
n	O
=	O
74	O
)	O
.	O

There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
PAI	O
-	O
1	O
levels	O
and	O
N	O
-	O
stage	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
,	O
presence	O
of	O
nodal	B-Cancer
metastases	I-Cancer
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
,	O
stage	O
grouping	O
(	O
p	O
=	O
<	O
0	O
.	O
01	O
)	O
and	O
extent	O
of	O
disease	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
total	O
group	O
and	O
the	O
SCC	B-Cancer
subgroup	O
,	O
but	O
not	O
adenocarcinoma	B-Cancer
.	O

There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
PAI	O
-	O
1	O
levels	O
and	O
T	O
-	O
stage	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
total	O
group	O
,	O
and	O
survival	O
status	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
SCC	B-Cancer
subgroup	O
alone	O
.	O

uPA	O
and	O
uPAR	O
levels	O
were	O
not	O
significantly	O
associated	O
with	O
tumour	B-Cancer
staging	O
or	O
survival	O
.	O

We	O
conclude	O
that	O
increased	O
PAI	O
-	O
1	O
antigen	O
levels	O
may	O
be	O
associated	O
with	O
a	O
decreased	O
survival	O
in	O
patients	O
with	O
SCC	B-Cancer
.	O

